Sitagliptin and aprepitant launched in Japan
14 December 2009
Ian Haydock
Please Login to read the full article.
14 December 2009
Ian Haydock
ian.haydock@informa.com
Two Merck & Co products, Januvia (sitagliptin) for diabetes and Emend (aprepitant) for chemotherapy-induced nausea and vomiting, have been launched in Japan, on the day of their reimbursement price listing on December 11th.
Both were developed and commercialised with the local firm
Ono Pharmaceutical,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Mitsubishi Tanabe's DPP-4 inhibitor teneligliptin filed in first market
- EC approval for BI/Lilly's one-dosage Trajenta for type 2 diabetes
- Three month review delay in US sets Takeda's alogliptin further back in diabetes
- EU's CHMP positive on Boehringer and Lilly's linagliptin
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
